ASCRS Guidelines: Anal Squamous Cell Cancer Management

Join us for a detailed clinical breakdown of the 2018 American Society of Colon and Rectal Surgeons (ASCRS) Clinical Practice Guidelines for Anal Squamous Cell Cancer. In this episode, we dive into the virology, staging nuances, landmark trial data, and treatment paradigms every practicing surgeon, oncologist, and board candidate needs to master.

Key Topics Covered in This Episode:

• Etiology & Risk Factors: The oncogenic role of HPV (serotypes 16 & 18), the field defect within the anal transitional zone (ATZ), and independent risk factors such as cigarette smoking and immunosuppression.

• Anatomic Classification: Distinguishing anal canal vs. perianal lesions using gluteal distraction and the strict 5 cm distance rule.

• Pathology & Biomarkers: Implementing the LAST two-tiered terminology (LSIL vs. HSIL), why the term "Bowen's disease" is obsolete, and using p16 and Ki-67 biomarkers to guide diagnosis.

• Screening & High-Resolution Anoscopy (HRA): Addressing the low specificity of anal cytology swabs, the mechanism of aceto-white staining during HRA, and when expectant management is acceptable.

• HPV Vaccination Rule: Why secondary HPV vaccination is not recommended for treating existing dysplasia (Grade 2A).

• Staging Pitfalls: Why anal SCC staging relies on maximum diameter rather than depth of wall invasion, and why sphincter muscle invasion does not upgrade a tumor to T4.

• Definitive Chemoradiation (The Nigro Protocol): The shift away from primary APRs, radiation dosing limits, and trial evidence (RTOG 9811 & ACT II) proving why 5-FU + Mitomycin C remains superior to Cisplatin.

• Surgical Exceptions & Survivorship: Narrow criteria for wide local excision alongside essential pre-treatment counseling for fertility preservation and post-radiation vaginal stenosis.